For subscription or membership programs, present total costs and key terms plainly (medication, labs, consults, cancellation, and recurring billing)
Common Side Effects (Both Oral and Injectable): Gastrointestinal Issues: These are the most common side effects for all GLP-1 medications: Nausea: Oral semaglutide (Rybelsus): 11-20% of patients Injectable semaglutide (Wegovy): 44% of patients Injectable tirzepatide (Zepbound): 30-37% of patients Why the difference: Lower bioavailability of oral medication means less systemic exposure, potentially resulting in fewer GI side effects
In MAESTRO-NASH, a phase III RCT recruiting 966 biopsy-proven MASLD patients with MASH and F2-F3 fibrosis, were randomized to three arms: placebo (n=321), resmetirom 80 mg (n=322) and resmetirom 100 mg (n=323), one pill per day
Likewise, structured workflows help researchers maintain reliable documentation standards throughout ongoing studies